A high-level government panel has concluded there is no increased risk of blood clotting so far linked to Covid vaccines Covishield and Covaxin.
The assurance from the National Adverse Events Following Immunization (AEFI) Committee comes after several European nations temporarily paused the rollout of AstraZeneca vaccine over blood clot fears. Last week, leading EU countries said they would resume the use of vaccine as the European medical regulator said the jab is "safe and effective".
The govt committee said it has analysed over 400 major adverse reactions during the ongoing vaccination drive and found that there is no unusual bleeding or clotting manifestations either with Covishield or Covaxin.